Follow-up Study of 10-day Sequential Therapy on Eradication of Helicobacter pylori

Helicobacter pylori (H. pylori) is closely related with chronic gastritis, peptic ulcer, gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoina. However. the efficacy of standard triple therapy is decreasing in recent years. Aims: To compare the efficacy of H. pylori eradication with 10-day sequential therapy and standard triple therapy. Methods: A total of 106 patients with peptic ulcer, chronic erosive gastritis and atrophic gastritis who were H. pylori positive proved by rapid urease test (RUT) and ~(14)C-urea breath test (~(14)C-UBT) were randomly divided into two groups. Fifty-six patients were administered with rabeprazole-based 10-day sequential therapy and 50 patients received rabeprazole-based 10-day standard triple therapy. RUT and ~(14)C-UBT were reexamined 4 weeks after a course of treatment to evaluate eradication of H. pylori. The recurrence of H. pylori was assessed by ~(14)C-UBT one-year after eradication treatment of H. pylori. Results: Ninety-three patients completed the study. The H. pylori eradication rates by intention-totreat (ITT) analysis and by per protocol (PP) analysis in 10-day sequential therapy group were significantly higher than those in 10-day standard triple therapy group (ITT: 89.3% vs. 62.0%, P0.01; PP: 94.3% vs. 77.5%, P0.05). The incidence of adverse reactions (7.1% vs. 30.0%, P0.01) and recurrence rate of H. pylori after one-year follow-up (6.0% vs.25.8%, P0.01) in 10-day sequential therapy group were significantly lower than those in 10-day standard triple therapy group. Conclusions: In the present study, rabeprazole-based 10-day sequential therapy has achieved a high eradication rate of H. pylori with good patient compliance and less adverse reactions.